CN102525904A - Stable felbinac gel and preparation method thereof - Google Patents
Stable felbinac gel and preparation method thereof Download PDFInfo
- Publication number
- CN102525904A CN102525904A CN2012100267507A CN201210026750A CN102525904A CN 102525904 A CN102525904 A CN 102525904A CN 2012100267507 A CN2012100267507 A CN 2012100267507A CN 201210026750 A CN201210026750 A CN 201210026750A CN 102525904 A CN102525904 A CN 102525904A
- Authority
- CN
- China
- Prior art keywords
- felbinac
- gel
- triethanolamine
- ethanol
- glycerol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a stable felbinac preparation, in particular to stable felbinac gel and a preparation method of the stable felbinac gel. Trolamine is used as pH conditioning agents and solubilizers, glycerol is used as dissolving assisting, moisture preservation, stability and absorption promoting agents and ethanol and water are used as solvents for forming a solvent system to be combined with a preparation process, so few relevant substances are degraded in the felbinac preparation process, and the finally prepared felbinac gel has the advantages that the color and luster are translucent, pure white effect, stability and no stimulation are realized, and the prepared felbinac gel is suitable for industrial production.
Description
Technical field
The present invention relates to a kind of stable felbinac preparation, further relate to a kind of stable felbinac gel and preparation method thereof.
Background technology
Felbinac (Felbinac) is NSAID (NSAID); It is the active metabolite of fenbufen (Fenbufen); Be widely used in osteoarthrisis deformans knee, scapulohumeral periarthritis, tenosynovitis, tennis elbow, peritendinitis, myalgia clinically, the easing pain and diminishing inflammation of soft tissue injury, traumatic swelling pain etc.Can cause gastrointestinal upset during oral NSAID, but transdermal administration can be avoided above untoward reaction effectively.At present, some percutaneous absorption type NSAID that abroad gone on the market are noticeable, and the felbinac ointment (3%) that goes on the market in Japan is exactly one of them.Felbinac ointment is developed by Pfizer; 1986 first in Japan listing, and trade name is to be applied to affected part in right amount 2 to 4 times
every day.Felbinac ointment is directly brought into play drug effect at target site through a kind of drug delivery; It is applied to pars affecta skin; The felbinac of effective dose is soaked into be diffused into pathological tissues; Bring into play partial easing pain and diminishing inflammation effect, avoided the systemic side effects such as gastrointestinal tract disorder of oral NSAID, its effectiveness and safety obtain clinical extensive approval.
ointment selects for use diisopropanolamine (DIPA) and an amount of ethanol/water as solvent system, and wherein diisopropanolamine (DIPA) is carbomer as pH regulator agent, ethanol/water as solvent, ointment base.The said preparation composition is used and is promoted in China and is subject to many limitations, and on the one hand, diisopropanolamine (DIPA) does not have legal source in China, is not suitable for the final production and the listing of medicine; O'clock viscosity is the strongest in pH6~12 for carbomer on the other hand, contradicts with the dissolubility of felbinac; Moreover; Felbinac is as nonsteroidal antiinflammatory drug, to wet, heat is responsive, and the gelation process of carbomer must could be accomplished through heating; One side needs heating to impel the quick and complete swelling of gel to shorten the manufacturing cycle of product in this process; The physicochemical property of considering felbinac self on the other hand must guarantee principal agent stability again, and its related substance is not significantly improved in the preparation process, and this is a technological challenge beyond doubt to one skilled in the art.
Summary of the invention
The object of the present invention is to provide a kind of principal agent felbinac few solvent composition of catabolite in the preparation process of guaranteeing.
The object of the present invention is to provide that a kind of appearance character is excellent, stable good, the felbinac gel that is fit to suitability for industrialized production of the quality of the pharmaceutical preparations.
The object of the present invention is to provide the method for preparing of above-mentioned felbinac gel.
First aspect of the present invention is to provide a kind of felbinac few solvent composition of catabolite in the preparation process of guaranteeing, this solvent composition is glycerol, triethanolamine, ethanol-water solution.Wherein triethanolamine plays the pH regulator agent and the felbinac solubilising of gel, and glycerol plays solubilising, stablizes, preserves moisture, promotes absorbent, and alcohol-water is a solvent, and concentration of ethanol has played antibacterial antiseptical effect.
Above-mentioned solvent system is characterised in that: the concentration of glycerol is 2~5%, and the concentration of triethanolamine is 3.6~6.5%, and alcoholic solution is selected from 30~50% alcoholic solution.
Through contrasting with diisopropanolamine (DIPA)-ethanol/water system, the stability of felbinac in solvent system of the present invention obviously is superior to the latter.Its advantage is the system stability of preparation, is in particular in that preparation has good appearance character: placed 10 days for 0~4 ℃ at 60 ℃ of high temperature and low temperature, and not stratified; Principal agent is non-crystallizable separates out invariant color.Its related substances is lower and have a higher Transdermal absorption curative effect.
Second aspect of the present invention provides a kind of prescription of stable felbinac gel and forms and preparation method thereof.
Said felbinac gel is characterized in that the prescription of this gel consists of felbinac, carbomer 934, triethanolamine, glycerol, ethanol and water.
Said felbinac gel is characterized in that the prescription composition as follows, is that 100g is in the prescription gross weight:
The method for preparing of said felbinac gel is characterized in that being that this method for preparing may further comprise the steps:
1. the carbomer of recipe quantity is put in an amount of purified water, abundant swelling adds the glycerol of recipe quantity, stirs, and the triethanolamine that adds half amount more fully stirs and makes into blank gel, and is subsequent use;
2. the felbinac of recipe quantity is put in an amount of 30~50% ethanol, added the surplus triethanolamine, stirring and dissolving;
3. medicinal liquid is slowly poured in the blank gel, and incorporated into gel with ethanol water flushing and add to full dose, constantly stir;
4. flexible pipe sterilization, subsequent use;
5. article are measured pH value and content in the middle of;
6. filling sleeve;
7. inspection entirely, packing, warehouse-in.
The advantage that the present invention gives prominence to is to have developed gel to the existing issue of felbinac ointment formulation; Through selecting good solvent system; Promptly adopt triethanolamine be pH regulator agent and solubilizing agent, glycerol as solubilising, preserve moisture, stable and absorption enhancer, ethanol/water combine preparation technology as the solvent system of solvent composition; Make felbinac related substance degraded in the preparation process less; The felbinac gel color and luster that finally makes is translucent, pure white, stable, non-stimulated, is suitable for suitability for industrialized production.
The specific embodiment
Below further specify the present invention through embodiment, but do not limit summary of the invention.
The stability of embodiment one felbinac in different basifier system
The kind and the consumption of table 1 felbinac gel organic amine
Can know by last table: 1. since MEA than large usage quantity, intrinsic colour is darker, prepare for yellow translucent, because the color of solution can influence the color of gel.And diisopropanolamine (DIPA), triethanolamine consumption are less relatively, and intrinsic colour is shallow, and the gel outward appearance of making is superior to MEA.Triethanolamine is than the diisopropanolamine (DIPA) medicinal specification that more is easy to get, and the source cost that is easy to get is lower, is final selection therefore.2. alcoholic acid adding has improved the dissolubility and the dissolution velocity of felbinac, has synergism, and 20% ethanol has antibiotic antisepsis concurrently simultaneously, is the composition of stablizing and simplifying of this gel systems.
Embodiment two carbomer 934 consumptions are selected
The consumption of table 2 carbomer 934 is confirmed
Carbomer 934 concentration is 1.0~1.2%, best 1.2%.Less than this ratio, gel viscosity is not enough, and smearing the thin local application of medicine layer drug level can't guarantee.Increase for the time of production gelation greatly greater than this ratio, be unfavorable for producing and realize.This gel is a piece grain even, fine and smooth, no cementation, when room temperature, keeps gluey, does not dry up and does not liquefy.
Embodiment three cutaneous permeable agent kinds and consumption are selected
Table 3 cutaneous permeable agent kind and consumption are confirmed
The result shows, 1. when in the prescription when no ethanol and glycerol, transdermal absorption factor is below 1%, and when containing in the gel when having an appointment 40% ethanol and 2% glycerol, transdermal absorption factor is increased to about 19%, and the raising effect is obvious; 2. after adding azone, transdermal absorption factor does not have significant change, in view of glycerol preserve moisture and with the collaborative hydrotropy effect of triethanolamine, short cutaneous permeable agent selects for use the glycerol consumption to select 2% at least.
The related substance contrast of embodiment quaterphenyl acetic acid in the different solvents system
According to the detection method in the felbinac gel quality affects standard in the British Pharmacopoeia, the stability of felbinac in the different solvents system is investigated.
Table 4 related substance contrast test solvent for use system
Annotate: felbinac is 3.0g in the amount of every kind of solvent system, and 50% ethanol adds to 100g.
The stability of table 5 felbinac in the different solvents system
The stability of the content of felbinac in solvent system B, related substance, pH value all is superior to solvent system A.
The prescription and the preparation technology of embodiment quinquephenyl acetic acid gel
Prescription is formed: in the prescription gross weight is that 100g does
The optimizing prescriptions of table 6 felbinac gel
Preparation technology:
1. the carbomer of above-mentioned recipe quantity is put in an amount of purified water, abundant swelling adds the glycerol of recipe quantity, stirs, and the triethanolamine that adds half amount more fully stirs and makes into blank gel, and is subsequent use;
2. the felbinac of recipe quantity is put in an amount of 30%~50% ethanol, added the surplus triethanolamine, stirring and dissolving;
3. medicinal liquid is slowly poured in the blank gel, and incorporated into gel with ethanol water flushing and add to full dose, constantly stir;
4. flexible pipe sterilization, subsequent use;
5. article are measured pH value and content in the middle of;
6. filling sleeve;
7. inspection entirely, packing, warehouse-in.
Embodiment six felbinac gel influence factors test
Get test preparation 1 and reference preparation 1 (
ointment; 3%) an amount of sample; Respectively low temperature (about 4 ℃) high temperature (40 ℃, 60 ℃), high humidity (RH75%, RH92.5%) and illumination (4500lx) condition held 10 days; In the 10th day take a sample to check pH value, content and related substance, the result was following:
Table 7 felbinac gel influence factor result of the test
Annotate: character: under 4 ℃, it is that white is translucent that sample is placed 10 days gels, not layering, and principal agent is crystallize not; Under 60 ℃, sample is placed 10 days gels and is become faint yellow; Under 40 ℃, sample is placed 10 days outward appearances does not have significant change.
The result shows that test preparation and reference preparation unification show temperature and humidity responsive, and related substance changes more obvious, but the test preparation amplitude of variation is significantly less than reference preparation, and from the result, test preparation is superior to reference preparation.
Embodiment seven felbinac gel accelerated stability tests
It is an amount of to get test preparation 1 sample, 30 ± 2 ℃ of temperature, carries out accelerated stability test under 65 ± 5% conditions, takes a sample in 0 month, 1 month, 2 months, 3 months, 6 months and carries out the mensuration of character, pH value, content and related substance, and the result is following:
Table 8 felbinac gel accelerated stability result
Comprehensive above-mentioned result of the test can draw; The felbinac gel adopts that triethanolamine, glycerol, ethanol/water are excellent as the product appearance character that solvent system and corresponding preparation technology make, quality stability good, related substance is few, compares existing product and has a clear superiority in.
Claims (5)
1. a solution that comprises felbinac is characterized in that this solution composition is felbinac, glycerol, triethanolamine, ethanol-water solution.
2. solution according to claim 1, the concentration that it is characterized in that felbinac is 3%, and the concentration of glycerol is 2~5%, and the concentration of triethanolamine is 3.6~6.5%, and alcoholic solution is selected from 30~50% alcoholic solution.
3. a stable felbinac gel is characterized in that the prescription of this gel consists of felbinac, carbomer 934, triethanolamine, glycerol, ethanol and water.
5. according to the method for preparing of the described felbinac gel of arbitrary claim in claim 3 or 4, it is characterized in that may further comprise the steps:
1. the carbomer of recipe quantity is put in an amount of purified water, abundant swelling adds the glycerol of recipe quantity, stirs, and the triethanolamine that adds half amount more fully stirs and makes into blank gel, and is subsequent use;
2. the felbinac of recipe quantity is put in an amount of 30~50% ethanol, added the surplus triethanolamine, stirring and dissolving;
3. medicinal liquid is slowly poured in the blank gel, and incorporated into gel with ethanol water flushing and add to full dose, constantly stir;
4. flexible pipe sterilization, subsequent use;
5. article are measured pH value and content in the middle of;
6. filling sleeve;
7. inspection entirely, packing, warehouse-in.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100267507A CN102525904B (en) | 2012-02-08 | 2012-02-08 | Stable felbinac gel and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100267507A CN102525904B (en) | 2012-02-08 | 2012-02-08 | Stable felbinac gel and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102525904A true CN102525904A (en) | 2012-07-04 |
CN102525904B CN102525904B (en) | 2013-07-17 |
Family
ID=46334738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012100267507A Expired - Fee Related CN102525904B (en) | 2012-02-08 | 2012-02-08 | Stable felbinac gel and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102525904B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104262138A (en) * | 2014-08-22 | 2015-01-07 | 湖北美林药业有限公司 | 4-biphenylacetic acid and pharmaceutical composition thereof |
-
2012
- 2012-02-08 CN CN2012100267507A patent/CN102525904B/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
郭坚固等: "联苯乙酸搽剂的制备与质量研究", 《今日药学》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104262138A (en) * | 2014-08-22 | 2015-01-07 | 湖北美林药业有限公司 | 4-biphenylacetic acid and pharmaceutical composition thereof |
CN104262138B (en) * | 2014-08-22 | 2016-05-11 | 湖北美林药业有限公司 | A kind of felbinac compound and pharmaceutical composition thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102525904B (en) | 2013-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080305163A1 (en) | Butylphthalide soft gel capsule and its preparation procedure | |
CN103717213B (en) | The transdermal composition of ibuprofen and using method thereof | |
Hadebe et al. | Transdermal delivery of insulin by amidated pectin hydrogel matrix patch in streptozotocin-induced diabetic rats: effects on some selected metabolic parameters | |
CN106074453B (en) | Lappaconitine Gel emplastrum and preparation method thereof | |
CN110327339A (en) | A kind of compound Dextromethorphan oral administration solution and its preparation method and application | |
CN110946846B (en) | Loxoprofen sodium gel cream matrix without transdermal penetration enhancer and preparation method thereof | |
Yubero-Lahoz et al. | Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain | |
Liu et al. | Design of hydrogels of 5-hydroxymethyl tolterodine and their studies on pharmacokinetics, pharmacodynamics and transdermal mechanism | |
CN102293735B (en) | Antifungal imidazole medicament controlled-release gel and preparation method thereof | |
CN102614111A (en) | Glucosamine gel and preparation method thereof | |
CN103347522B (en) | Transdermal patch | |
CN101147735A (en) | Pharmaceutical composition for injection and its medicine box | |
CN102525904B (en) | Stable felbinac gel and preparation method thereof | |
CN104983710B (en) | A kind of preparation method of natural plant gum wafer | |
Chen et al. | Losartan potassium and verapamil hydrochloride compound transdermal drug delivery system: Formulation and characterization | |
Yeoh et al. | Development and characterisation of a topical methyl salicylate patch: effect of solvents on adhesion and skin permeation | |
CN105147642B (en) | A kind of transdermal patch containing Formoterol or its fumarate | |
CN101199514B (en) | Ketoralac ammonia butanetriol injection and preparing method thereof | |
CN106692033A (en) | Blank gel | |
CN115475152A (en) | External preparation of flurbiprofen and preparation method thereof | |
CN102824363B (en) | Antibacterial agent | |
CN108066339A (en) | A kind of pharmaceutical composition of Parecoxib Sodium | |
CN104069505A (en) | Percutaneous-absorption palonosetron patch and preparation method thereof | |
CN114588108A (en) | Oil-soluble solution containing insect-resistant agent and preparation method and application thereof | |
CN106924760B (en) | Diagnostic matrix composition for skin allergen patch test and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130717 Termination date: 20200208 |